Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Phenylphenol SCHEMBL8158878 | 0.85 | ALDH1A1 (0.53) | THRBKDM4EALDH1A1HPGDGAA | |
| SCHEMBL16955402 | 0.82 | NPC1 (0.41) | THRBKDM4EALDH1A1HPGDMAOB | |
| SCHEMBL10442735 | 0.80 | HPGD (0.46) | THRBKDM4EALDH1A1HPGDMAOB | |
| SCHEMBL1873518 | 0.80 | KMT2A (0.41) | THRBKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL623498 | 0.80 | ALDH1A1 (0.60) | KDM4EALDH1A1HPGDGAASMN1; SMN2 | |
| SCHEMBL28179499 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1HPGDMAPTGAA | |
| SCHEMBL697650 | 0.78 | BRPF1 (0.46) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1447795 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| SCHEMBL29616326 | 0.78 | LMNA (0.66) | KDM4EALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL27598806 | 0.78 | HSP90AB1 (0.47) | THRBKDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192174-A | Novel biphenyl carboxylic FXR agonist, preparation method thereof and application thereof as medicine | 广东药科大学 | 2024-12-27 | — | — | CN | disclosed |
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| WO-2010074088-A1 | CYCLIC AMINE COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1305024-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | Alteon, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | THRB 2609/4885KDM4E 3095/4885ALDH1A1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.